Aspire Biopharma completes $30M acquisition of Dura Driver Control Systems

Aspire Biopharma Holdings, Inc.

Acquired 100% of DCS for ~$30.0M cash; DCS becomes wholly owned subsidiary on Aug 6, 2026.
DCS FY2025 revenue $209.5M and Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.
Entered $22.5M senior secured revolving credit facility to fund acquisition, along with cash on hand.
Issued $3.75M convertible notes for $3.0M (20% OID), conversion at $8.00/share for working capital.
DCS CEO Hans Vorstenbosch stays; 11 plants, 310+ patents, 50+ customers, top-10 OEM avg 28-yr relationship.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.